The filing is a standard advance notice for a small insider sale by a director. No material impact on the stock is expected. Monitor for any subsequent Form 4 filings to confirm execution.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vertex Pharmaceuticals director Nancy Thornberry filed a Form 144 notice of intent to sell 1,000 shares of common stock, with an estimated aggregate market value of approximately $547,860 based on the filing. The shares were acquired through restricted stock vesting in December 2024 and May 2025. This is a routine, small disposition relative to the company's $137.6B market cap and the director's likely total holdings.
Key Facts
- Nancy Thornberry, a director of Vertex Pharmaceuticals, filed a Form 144 on November 16, 2026.
- The proposed sale is for 1,000 shares of common stock.
- Estimated aggregate market value of the sale is $547,860.
- Shares were acquired via restricted stock vesting on December 5, 2024 (499 shares) and May 1, 2025 (501 shares).
- The sale is planned for execution on or after November 16, 2026, through Fidelity Brokerage Services LLC.
Financial Impact
Proceeds of approximately $547,860, representing about 0.0004% of Vertex's $137.6B market cap.
Risk Factors
- The sale may not be executed; Form 144 is an intent to sell, not a completed transaction.
- No unusual insider selling pattern detected; this appears to be a routine portfolio diversification move.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-008021 |
| Document: 0001959173-26-008021-index.html | 0001959173-26-008021 |
| Document: 0001959173-26-008021.txt | 0001959173-26-008021 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Viewing Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers